oesophageal cancer is less strong. There are, however, similarities between the carcinogenic process and the chemopreventive potential of NSAIDs in these organs (Table) . Oesophageal cancer is also associated with the excessive production of prostaglandin E231 and two published reports have documented the ability of NSAIDs to prevent and reverse chemically induced oesophageal cancers in rodents.32 33 found that aspirin consumption offered no protection against oesophageal cancer. Both studies reported an inverse correlation between aspirin consumption and colorectal cancer risk. There are, however, good pharmacological reasons to suspect that regular NSAID consumption does offer protection against oesophageal squamous cell carcinoma and adenocarcinoma. Chronic oesophagitis, an important precancerous oesophageal lesion and inflammation, is associated with the excessive mucosal production of prostaglandin E2.36 The raised prostaglandin/leukotriene ratio may contribute to carcinogenesis because prostaglandin E2 seems to be carcinostimulant in the oesophagus while lipoxygenase metabolites are protective.37 NSAIDs can prevent and reverse oesophageal inflammation, and biochemically this would parallel a restoration of the low prostaglandin/ leukotriene ratio associated with the normal oesophageal mucosa. NSAID intervention may be particularly useful in the areas of the world with a high incidence of chronic oesophagitis and oesophageal squamous cell carcinoma.
Barrett's oesophagus is an important precancerous lesion and is thought to represent an adaptive response to longstanding reflux injury. Barrett's oesophagus may be prevented by NSAIDs because prostaglandin E2 seems to drive the cycle of dysmotility, duodenogastric reflux, mucosal injury, aggravated dysmotility, and further duodenogastric reflux.36 37 Objections to NSAID intervention Because of the major public health and economic implications of NSAID cancer chemoprevention, it is essential that all recommendations are evidence based. NSAIDs can damage the gastrointestinal tract, liver, and kidneys and thus the potential benefit would need to be balanced against the risk of adverse effects. For cardiovascular disease aspirin chemoprevention with an optimum dose of 160 mg daily has been associated with a favourable benefit versus risk ratio. This does not, however, justify large scale aspirin chemoprevention because the doses of aspirin required for cancer protection may be greater than the antiplatelet dose.39 In the absence of an evidence dose related carcinogenic grading system, caution is required because biased messages reaching the general public may be misinterpreted. For example, advocating the benefit of aspirin without highlighting potential risk may lead to the inappropriate or excessive consumption. A multidisciplinary scientific approach is therefore required to produce evidence based guidelines before chemoprevention strategies can be implemented.
In high risk cohorts where NSAID chemoprevention trials appear justifiable, additional measures could be used to reduce the risk of NSAID toxicity. These could include the use of enteric coated aspirin, NSAIDs candidates for NSAID or placebo randomised controlled trials. A carcinogenic grading system for oesophageal and colorectal cancer should define individual or population cancer risks, or both, as low, moderate, medium or high. Such a grading system should be versatile to accommodate regional risk factors, such as traditional dietary practices, and could be scored by assessing factors such as alcohol intake, age, demographics, dietary habits, genetic predisposition, and the presence or severity of precancerous lesions. The advantage of a quantifiable system is that NSAID efficacy could be monitored as a function of baseline risk, while changes in cancer risk may require proportionate increases/decreases in NSAID dosage and frequency. In anticipation of this, future epidemiological studies should consider the relation between aspirin consumption, baseline cancer risk, and resultant cancer incidence. Data from these studies will support the design of a dose related carcinogenic grading system. The design of this system will require a multi-disciplinary/multi-national approach, however, it would herald a break through in cancer prevention because evidence based NSAID intervention strategies could be implemented. Finally, NSAIDs may also be useful in the treatment of oesophageal carcinoma.3 Tumoricidal NSAIDs may induce carcinoma regression and could also help to reduce the risk of side effects from radiotherapy and surgery.
